Our Commitment to AI

At Tec de Monterrey, we aim to understand and apply artificial intelligence (AI) in education, seeing it as a key driver of innovation. We focus on helping our students develop both cross-disciplinary and specialized AI-related skills, preparing them for diverse professional and workplace scenarios, always from an ethical perspective.

Through research, education, and collaboration across disciplines, we promote AI-driven innovation, equipping our faculty and staff to use it efficiently and responsibly, ensuring a positive impact on our institution and community.

Our philosophy is to use AI ethically, respecting human dignity, promoting integrity and autonomy, and ensuring a safe environment aligned with our institutional values, addressing challenges and opportunities with agility. 

Discover the World of AI: Beyond Fiction

We’ve all likely heard the term “artificial intelligence,” but do we know what it means? AI is about developing technologies that enable machines to perform complex tasks requiring skills like reasoning, problem-solving, understanding language, and analyzing data. UNESCO describes it as a set of tools that mimic or even surpass some human capabilities, such as creativity, language, and logical reasoning. 

How does it work? AI is based on key principles: learning from data (machine learning), processing information through artificial neural networks, and optimizing decisions to make them more efficient. Thanks to these principles, AI systems can identify patterns, adapt to new situations, and improve their performance over time, mimicking some aspects of human thought processes. 

From ANI to AGI: AI That Transforms 

Are there different types of AI? Are they the same? What are they? Artificial intelligence (AI) is divided into two main types: Artificial Narrow Intelligence (ANI) and Artificial General Intelligence (AGI). 

Source: Sabzalieva, E., & Valentini, A. (2023). ChatGPT and Artificial Intelligence in Higher Education: Quick Start Guide.

Develops and optimizes bioengineering platforms to produce new commercial products focused on the early detection and prevention of metabolic disorders associated with obesity.

What does this unit do?

1. Bioengineering of processes to identify and produce bioactives.
2. Development of medical devices for early detection and monitoring.
3. Engineering of delivery systems and detection of molecules.
4. Generation of clinical interventions that positively impact society.

Products and services developed by the unit

• Selection of novel biomolecules associated with metabolic diseases.
• Medical devices (based on new technologies, user-friendly and accessible) for the early detection and monitoring of metabolic diseases.
• Real-time detection sensors of biomarkers associated with metabolic diseases.
• Improvement of the performance of existing platforms for the early detection and monitoring of metabolic diseases.
• Prevention and treatment strategies for metabolic diseases and their complications.
• Strategies for the prediction and monitoring of risk of metabolic diseases.

Dr. Omar Lozano García
Unit leader. Research Professor

Design of advanced materials for drug delivery systems and probes, preclinical studies, nanosafety, nano-bio-interactions.
Get to know his work

Dr. Marco Antonio Rito Palomares
Director of the Institute for Obesity Research

Development of early detection technologies, drug delivery systems and strategies based on aqueous two-phase systems.
Get to know his work

Dr. Jorge Alejandro Benavides Lozano
Research Professor

Bioengineering, Bioprocesses, Bioproduct formulation, Bioactive discovery and characterization, Synthetic biology.
Get to know his work

Dr. Karla Patricia Mayolo Deloisa
Research Professor

Specialist in nanoparticle formulation, protein modification and bioprocesses.
Get to know her work

Dr. Mirna Alejandra González González
Research Professor

Development of flexible bioengineering platforms for biomedical applications.
Get to know her work

Develops and optimizes bioengineering platforms to produce new commercial products focused on the early detection and prevention of metabolic disorders associated with obesity.

What does this unit do?

1. Bioengineering of processes to identify and produce bioactives.
2. Development of medical devices for early detection and monitoring.
3. Engineering of delivery systems and detection of molecules.
4. Generation of clinical interventions that positively impact society.

Products and services developed by the unit

• Selection of novel biomolecules associated with metabolic diseases.
• Medical devices (based on new technologies, user-friendly and accessible) for the early detection and monitoring of metabolic diseases.
• Real-time detection sensors of biomarkers associated with metabolic diseases.
• Improvement of the performance of existing platforms for the early detection and monitoring of metabolic diseases.
• Prevention and treatment strategies for metabolic diseases and their complications.
• Strategies for the prediction and monitoring of risk of metabolic diseases.

Dr. Omar Lozano García
Unit leader. Research Professor

Design of advanced materials for drug delivery systems and probes, preclinical studies, nanosafety, nano-bio-interactions.
Get to know his work

Dr. Marco Antonio Rito Palomares
Director of the Institute for Obesity Research

Development of early detection technologies, drug delivery systems and strategies based on aqueous two-phase systems.
Get to know his work

Dr. Jorge Alejandro Benavides Lozano
Research Professor

Bioengineering, Bioprocesses, Bioproduct formulation, Bioactive discovery and characterization, Synthetic biology.
Get to know his work

Dr. Karla Patricia Mayolo Deloisa
Research Professor

Specialist in nanoparticle formulation, protein modification and bioprocesses.
Get to know her work

Dr. Mirna Alejandra González González
Research Professor

Development of flexible bioengineering platforms for biomedical applications.
Get to know her work

Experimental prevention and treatment therapies in preclinical models, which lay the foundations for clinical studies of patients with metabolic disease and obesity.

What does this unit do?

In this unit, we develop novel therapies of synthetic molecules, natural products, immunomodulatory strategies, cellular and molecular therapy, and controlled release systems, which can generate proofs-of-concept and personalized treatments (drugs) for metabolic diseases.

Experimental medicine

Experimental medicine refers to deciphering the pathophysiological mechanisms of various diseases, identifying new therapeutic targets, and contributing to developing new drugs.

Although experimental medicine is widely developed with different approaches in Mexico, as in many countries worldwide, translating its major advances into cutting-edge and direct clinical applications is a constant challenge. Few groups in our country have achieved such transfer. Tecnologico de Monterrey has some successful examples in the transfer of experimental medicine, which has allowed the institution to lay the foundation to improve the coordination of efforts and transfer results from the laboratory to clinical practice.

Design of new drugs

In the context of obesity, some comorbidities such as hypertension, diabetes, and fatty liver require developing new drugs that reduce morbidity and mortality.

There is currently no ideal treatment for obesity and its comorbidities; for this reason, our health system seeks a new route for prevention and treatment with new drugs and innovative therapies that are more effective, specific, and with less risk of side effects.

Dr. Gerardo de Jesús García Rivas
Unit leader. Research Professor

Biochemistry, Biology, Biological Sciences.
More about his work

Dr. Noemí García Ramírez
Research Professor

Biology, Biological Sciences
More about her work

Dr. Marion Emilie Genevieve Brunck
Research Professor

Microbiology
More about her work

Dr. Flavio Fernando Contreras Torres
Researcher Professor

Physics and Chemistry
More about his work

Dr. Elena Cristina González Castillo
Research Professor

More about her work

Dr. Julieta Palomeque
Research Professor

More about her work

Dr. Guillermo Torre Amione
Rector of TecSalud

Biomedical sciences, cardiology, and immunological medicine
More about his work

Experimental prevention and treatment therapies in preclinical models, which lay the foundations for clinical studies of patients with metabolic disease and obesity.

What does this unit do?

In this unit, we develop novel therapies of synthetic molecules, natural products, immunomodulatory strategies, cellular and molecular therapy, and controlled release systems, which can generate proofs-of-concept and personalized treatments (drugs) for metabolic diseases.

Experimental medicine

Experimental medicine refers to deciphering the pathophysiological mechanisms of various diseases, identifying new therapeutic targets, and contributing to developing new drugs.

Although experimental medicine is widely developed with different approaches in Mexico, as in many countries worldwide, translating its major advances into cutting-edge and direct clinical applications is a constant challenge. Few groups in our country have achieved such transfer. Tecnologico de Monterrey has some successful examples in the transfer of experimental medicine, which has allowed the institution to lay the foundation to improve the coordination of efforts and transfer results from the laboratory to clinical practice.

Design of new drugs

In the context of obesity, some comorbidities such as hypertension, diabetes, and fatty liver require developing new drugs that reduce morbidity and mortality.

There is currently no ideal treatment for obesity and its comorbidities; for this reason, our health system seeks a new route for prevention and treatment with new drugs and innovative therapies that are more effective, specific, and with less risk of side effects.

Dr. Gerardo de Jesús García Rivas
Unit leader. Research Professor

Biochemistry, Biology, Biological Sciences.
More about his work

Dr. Noemí García Ramírez
Research Professor

Biology, Biological Sciences
More about her work

Dr. Marion Emilie Genevieve Brunck
Research Professor

Microbiology
More about her work

Dr. Flavio Fernando Contreras Torres
Researcher Professor

Physics and Chemistry
More about his work

Dr. Elena Cristina González Castillo
Research Professor

More about her work

Dr. Julieta Palomeque
Research Professor

More about her work

Dr. Guillermo Torre Amione
Rector of TecSalud

Biomedical sciences, cardiology, and immunological medicine
More about his work